Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

The novel treatment consists of a single shot which is made of special proteins called antibodies that bind to the site at ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Two new studies, one based on households in southeast Michigan and one involving hospitalized Japanese adults, compare ...

“This powerful technology has the potential not only to help control COVID-19 but to reduce the burden of respiratory ... for other common respiratory viruses such as seasonal influenza, avian flu and ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...